Condition 101 About Middle East Respiratory Syndrome

What is the definition of Middle East Respiratory Syndrome?

Middle East respiratory syndrome (MERS) is a mild to severe upper respiratory tract infection caused by a coronavirus that spreads from animals to humans (usually camels), but also amongst humans. Middle East respiratory syndrome is mainly found in Saudi Arabia and other Middle-Eastern countries.

What are the symptoms for Middle East Respiratory Syndrome?

Symptoms of Middle Eastern respiratory syndrome usually appear anywhere from 5 to 6 days after exposure but can occur between 2 to 14 days. The symptoms can be mild to severe. Individuals with mild infections may experience no symptoms or cold-like symptoms. The main symptoms of Middle Eastern respiratory syndrome include fever, coughing, and shortness of breath, while some individuals may also cough up blood or experience nausea and/or vomiting or diarrhea. Severe infections may develop in immunocompromised individuals, causing pneumonia or kidney failure. Middle Eastern respiratory syndrome has a death rate of around 30%.

What are the current treatments for Middle East Respiratory Syndrome?

Treatment for Middle Eastern respiratory syndrome involves supportive care. There is currently no vaccine or antiviral treatment available.

Top Global Doctors For Middle East Respiratory Syndrome

SL
Elite
Susanna P. Lau
Lika, CN
PW
Elite
Patrick C. Woo
Sar, CN
JT
Elite
Jaffar A. Tawfiq-Al
SA
AZ
Elite
Alimuddin I. Zumla
GB
YA
Elite
Yaseen M. Arabi
Riyadh, SA

Latest Advances On Middle East Respiratory Syndrome

  • Condition: Patients with Diabetes Amidst the Covid-19 Pandemic
  • Journal: Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • Treatment Used: Probiotics
  • Number of Patients: 0
  • Published —
This review of the literature examined data concerning gut microbiota influences on COVID-19 in patients with diabetes.

Clinical Trials For Middle East Respiratory Syndrome

Clinical Trial
  • Status: Not yet recruiting
  • Phase: Early Phase 1
  • Intervention Type: Drug
  • Participants: 30
  • Start Date: April 2021
Povidine-Iodine Effect on Nasal Mucosa Cilia in Rhinoplasty Patients
Clinical Trial
  • Status: Not yet recruiting
  • Phase: Phase 1/Phase 2
  • Intervention Type: Drug
  • Participants: 28
  • Start Date: March 2021
A Pilot, Randomized, Open-label Trial to Determine the Feasibility, Safety, Efficacy, and Pharmacokinetics of Nebulized HCQ01 for the Treatment of Patients With COVID-19 and Cancer